about
The ABC protein turned chloride channel whose failure causes cystic fibrosisStrict coupling between CFTR's catalytic cycle and gating of its Cl- ion pore revealed by distributions of open channel burst durations.Mutant cycles at CFTR's non-canonical ATP-binding site support little interface separation during gatingImproved fluorescence assays to measure the defects associated with F508del-CFTR allow identification of new active compounds.Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases.On the mechanism of MgATP-dependent gating of CFTR Cl- channelsProlonged nonhydrolytic interaction of nucleotide with CFTR's NH2-terminal nucleotide binding domain and its role in channel gating.Conformational changes in the catalytically inactive nucleotide-binding site of CFTR.Review. ATP hydrolysis-driven gating in cystic fibrosis transmembrane conductance regulator.In vivo phosphorylation of CFTR promotes formation of a nucleotide-binding domain heterodimer.Control of the CFTR channel's gatesInvolvement of F1296 and N1303 of CFTR in induced-fit conformational change in response to ATP binding at NBD2Increased apical Na+ permeability in cystic fibrosis is supported by a quantitative model of epithelial ion transport.CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.Mutations in the pore regions of the yeast K+ channel YKC1 affect gating by extracellular K+.Electrophysiological, biochemical, and bioinformatic methods for studying CFTR channel gating and its regulation.Mutations in the yeast two pore K+ channel YKC1 identify functional differences between the pore domains.Extracellular K+ and Ba2+ mediate voltage-dependent inactivation of the outward-rectifying K+ channel encoded by the yeast gene TOK1.Potentiation of the cystic fibrosis transmembrane conductance regulator by VX-770 involves stabilization of the pre-hydrolytic, O stateStructure of Transmembrane Helix 8 and Possible Membrane Defects in CFTRSTRUCTURE, GATING, AND REGULATION OF THE CFTR ANION CHANNELMultitarget CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach †
P50
Q24657572-E1E05DCA-9541-48D6-97C3-170CB67B80C3Q33666969-76EF4FD4-B35C-47FC-ADE1-47CC8EC74C48Q35018175-A5AFC18D-B234-40AC-82FA-A15676FF33B3Q36251047-663C4991-FA68-4163-9F2A-E2E9D44DB2E4Q36260001-51C99A46-0894-47F9-89FD-1A14F5B1406FQ36412358-F18BB51F-342B-460A-9A30-23BF5FC01D2BQ36447213-BC4FEDEE-8D0F-4529-9716-D5238D7E64C5Q36951968-839AF750-EA8D-488E-8166-F77BF719ACF1Q37310608-B76246E4-5C75-4A3E-B74E-AC1FAE864066Q38774272-D63D5F21-7DAF-4CF6-B398-7895DB9DD4A0Q41897223-8C4028BD-276D-4110-9177-B8D9CF17D11CQ42416978-CD8FE58F-B778-46E5-87A3-933DC053385DQ42439450-74BD00D5-708B-48A3-B985-7F8BD9C218CFQ42575484-34BD37A5-578C-4140-B7DE-A753389FF4FDQ42662713-A4B47A85-9B75-47E8-AB16-5F168FF991FDQ48673047-01F3B16C-9FBC-4639-81AD-119428AC651CQ48905305-3218C17D-2681-49F0-8152-E544FC1B04F1Q48960212-DD91C393-5F55-41F0-8C3A-66BD5C5A8980Q60643304-29AAB4CE-7D32-4870-A146-7232C2C496A9Q60643306-BF51457F-7B88-439E-B8EB-86B3BBB8CB1DQ90270716-09B8203C-5DFC-46CA-9B79-5AE28DB009CDQ91293661-7D671B06-806A-4B3C-A675-799EB9A33FF6
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Paola Vergani
@ast
Paola Vergani
@en
Paola Vergani
@es
Paola Vergani
@nl
Paola Vergani
@sl
type
label
Paola Vergani
@ast
Paola Vergani
@en
Paola Vergani
@es
Paola Vergani
@nl
Paola Vergani
@sl
prefLabel
Paola Vergani
@ast
Paola Vergani
@en
Paola Vergani
@es
Paola Vergani
@nl
Paola Vergani
@sl
P1053
C-2019-2008
P106
P1153
56273272300
P21
P2798
P31
P3829
P496
0000-0002-5422-4662